
    
      Although the anti-CD19 CAR-T cell therapies have gained significant results in patients with
      relapsed and refractory B-cell hematologic malignancies.

      There are patients who resisted anti-CD19 CAR-T cells or with CD19 negative relapse. To make
      further improvement, the investigators launch such a clinical trial using CD19 and CD22
      targeted prime CAR-T cells for patients with relapsed and refractory B Cell Lymphomato
      evaluate the efficacy and safety of CD19 and CD22 targeted prime CAR-T cell therapy.
    
  